New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
04:55 EDTCFN, CFN, CFN, JAZZ, JAZZ, JAZZ, RMD, RMD, RMD, VNDA, VNDA, VNDA, XNPT, XNPT, XNPTAssociated Professional Sleep Societies to hold annual meeting
28th Annual SLEEP Meeting is being held in Minneapolis on May 31-June 4.
News For CFN;JAZZ;RMD;VNDA;XNPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
08:12 EDTJAZZJazz Pharmaceuticals management to meet with Leerink
Subscribe for More Information
07:21 EDTJAZZUBS to hold a conference
Subscribe for More Information
May 18, 2015
12:24 EDTJAZZJazz Pharmaceuticals management to meet with Guggenheim
Subscribe for More Information
May 13, 2015
10:56 EDTRMDResMed declines sharply, levels to watch
Shares are trading close to the lows of the day at $54.95. At that price, next support is at $53.20. Resistance is at $56.65.
10:36 EDTRMDResMed pullback overdone on SERVE-HF missing endpoint, says Piper Jaffray
Subscribe for More Information
10:01 EDTRMDOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:25 EDTRMDResMed downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
05:39 EDTRMDResMed announces SERVE-HF study did not meet primary endpoint
ResMed announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was designed to assess whether the treatment of moderate to severe predominant central sleep apnea with Adaptive Servo-Ventilation therapy could reduce mortality and morbidity in patients with symptomatic chronic heart failure in addition to optimized medical care. The study did not show a statistically significant difference between patients randomized to ASV therapy and those in the control group in the primary endpoint of time to all-cause mortality or unplanned hospitalization for worsening heart failure. The results from SERVE-HF are preliminary and will be submitted for future publication after further analysis. A preliminary analysis of the data identified a statistically significant 2.5% absolute increased risk of cardiovascular mortality for those patients in the trial who received ASV therapy per year compared to those in the control group. In the study, the cardiovascular mortality rate in the ASV group was 10% per year compared to 7.5% per year in the control group. There were no issues associated with the performance of the ASV therapy device in the trial. ResMed is working with global regulatory authorities to proactively revise the labels and instructions for use for ResMed ASV devices to include a contraindication for people with symptomatic chronic heart failure. The company is also proactively informing healthcare providers, physicians, and patients of the cardiovascular safety signal observed in SERVE-HF.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use